Urologic Oncology

Chapter

Abstract

Over half of newly diagnosed cancers occur in individuals >65 years of age. With our growing elderly population, this proportion will likely to increase in the upcoming years. The incidence of urologic cancers including bladder, prostate, and kidney cancer increases with age. It is therefore important for urologists who treat urologic malignancies to be aware of the unique challenges of treating cancer in this age group. Predicted physiologic changes that occur with aging can impact surgical planning and administration of chemotherapeutic agents. The goals of cancer treatment in the elderly should include minimizing the impact of cancer treatment on quality of life and maximizing long-term functioning and independence.

Keywords

Placebo Migration Toxicity Filtration Europe 

References

  1. 1.
    Etzioni DA, Liu JH, Maggard MA, Ko CY. The aging population and its impact on the surgery workforce. Ann Surg. 2003;238:170–7.PubMedGoogle Scholar
  2. 2.
    Pasetto LM, Lise M, Monfardini S. Preoperative assessment of elderly cancer patients. Crit Rev Oncol Hematol. 2007;64:10–8.PubMedGoogle Scholar
  3. 3.
    Shariat SF, Milowsky M, Droller MJ. Bladder cancer in the elderly. Urol Oncol. 2009;27:653–67.PubMedGoogle Scholar
  4. 4.
    Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16:1582–7.PubMedGoogle Scholar
  5. 5.
    Conwell Y, Forbes NT, Cox C, Caine ED. Validation of a measure of physical illness burden at autopsy: the cumulative illness rating scale. J Am Geriatr Soc. 1993;41:38–41.PubMedGoogle Scholar
  6. 6.
    Sanchez-Salas R, Prapotnich D, Rozet F, et al. Laparoscopic radical prostatectomy is feasible and effective in ‘fit’ senior men with localized prostate cancer. BJU Int. 2010;106:1530–6.PubMedGoogle Scholar
  7. 7.
    Guzzo TJ, Allaf ME, Pierorazio PM, et al. Perioperative outcomes of elderly patients undergoing laparoscopic renal procedures. Urology. 2009;73:572–6.PubMedGoogle Scholar
  8. 8.
    Rubenstein LZ, Stuck AE, Siu AL, Wieland D. Impacts of geriatric evaluation and management programs on defined outcomes: overview of the evidence. J Am Geriatr Soc. 1991;39:8S–16S; discussion 7S–8S.Google Scholar
  9. 9.
    SEER cancer statistics review. (1975–2002). National Cancer Institute. www.seer.cancer.gov/csr/1975_2002 Accessed Feb 2010.
  10. 10.
    Pal SK, Katheria V, Hurria A. Evaluating the older patient with cancer: understanding frailty and the geriatric assessment. CA Cancer J Clin. 2010;60:120–32.PubMedGoogle Scholar
  11. 11.
    Gronberg H. Prostate cancer epidemiology. Lancet. 2003;361:859–64.PubMedGoogle Scholar
  12. 12.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2011;60:277–300.Google Scholar
  13. 13.
    Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581–92.PubMedGoogle Scholar
  14. 14.
    Heinzer H, Steuber T. Prostate cancer in the elderly. Urol Oncol. 2009;27:668–72.PubMedGoogle Scholar
  15. 15.
    Crawford ED. Epidemiology of prostate cancer. Urology. 2003;62:3–12.PubMedGoogle Scholar
  16. 16.
    Mohile SG, Lachs M, Dale W. Management of prostate cancer in the older man. Semin Oncol. 2008;35:597–617.PubMedGoogle Scholar
  17. 17.
    Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95:868–78.PubMedGoogle Scholar
  18. 18.
    Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA. 2001;285:2750–6.PubMedGoogle Scholar
  19. 19.
    Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol. 2011;29:1335–41.PubMedGoogle Scholar
  20. 20.
    Boulos DL, Groome PA, Brundage MD, et al. Predictive validity of five comorbidity indices in prostate carcinoma patients treated with curative intent. Cancer. 2006;106:1804–14.PubMedGoogle Scholar
  21. 21.
    Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22:2141–9.PubMedGoogle Scholar
  22. 22.
    Andriole GL, Crawford ED, Grubb 3rd RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310–9.PubMedGoogle Scholar
  23. 23.
    Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–8.PubMedGoogle Scholar
  24. 24.
    Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, Catalona WJ. What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol. 2011;29:464–7.PubMedGoogle Scholar
  25. 25.
    Studer UE, Collette L. What can be concluded from the ERSPC and PLCO trial data? Urol Oncol. 2010;28:668–9.PubMedGoogle Scholar
  26. 26.
    Konety BR, Cowan JE, Carroll PR. Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE. J Urol. 2008;179:1797–803; discussion 803.Google Scholar
  27. 27.
    U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:185–91.Google Scholar
  28. 28.
    Greene KL, Albertsen PC, Babaian RJ, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009;182:2232–41.PubMedGoogle Scholar
  29. 29.
    Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW. Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2011;60:99–119.Google Scholar
  30. 30.
    Caire AA, Sun L, Robertson CN, et al. Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75. Urology. 2010;75:1122–7.PubMedGoogle Scholar
  31. 31.
    Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. JAMA. 2006;296:2336–42.PubMedGoogle Scholar
  32. 32.
    Lu-Yao G, Stukel TA, Yao SL. Prostate-specific antigen screening in elderly men. J Natl Cancer Inst. 2003;95:1792–7.PubMedGoogle Scholar
  33. 33.
    Zeliadt SB, Hoffman RM, Etzioni R, Gore JL, Kessler LG, Lin DW. Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst. 2010;103:520–3.Google Scholar
  34. 34.
    Schaeffer EM, Carter HB, Kettermann A, et al. Prostate specific antigen testing among the elderly—when to stop? J Urol. 2009;181:1606–14; discussion 13–4.Google Scholar
  35. 35.
    Roberts CB, Albertsen PC, Shao YH, et al. Patterns and correlates of prostate cancer treatment in older men. Am J Med. 2011;124:235–43.PubMedGoogle Scholar
  36. 36.
    Wong YN, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA. 2006;296:2683–93.PubMedGoogle Scholar
  37. 37.
    D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–74.PubMedGoogle Scholar
  38. 38.
    Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006;98:715–7.PubMedGoogle Scholar
  39. 39.
    Kattan MW, Potters L, Blasko JC, et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology. 2001;58:393–9.PubMedGoogle Scholar
  40. 40.
    Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 2000;18:3352–9.PubMedGoogle Scholar
  41. 41.
    Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol. 2009;27:4300–5.PubMedGoogle Scholar
  42. 42.
    Ficarra V, Cavalleri S, Novara G, Aragona M, Artibani W. Evidence from robot-assisted laparoscopic radical prostatectomy: a systematic review. Eur Urol. 2007;51:45–55; discussion 6.Google Scholar
  43. 43.
    Walsh PC. Anatomic radical prostatectomy: evolution of the surgical technique. J Urol. 1998;160:2418–24.PubMedGoogle Scholar
  44. 44.
    Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106–31.PubMedGoogle Scholar
  45. 45.
    Droz JP, Balducci L, Bolla M, et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int. 2010;106:462–9.PubMedGoogle Scholar
  46. 46.
    Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68–80.PubMedGoogle Scholar
  47. 47.
    Kerr LA, Zincke H. Radical retropubic prostatectomy for prostate cancer in the elderly and the young: complications and prognosis. Eur Urol. 1994;25:305–11; discussion 11–2.Google Scholar
  48. 48.
    Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. N Engl J Med. 2002;346:1138–44.PubMedGoogle Scholar
  49. 49.
    Shikanov S, Desai V, Razmaria A, Zagaja GP, Shalhav AL. Robotic radical prostatectomy for elderly patients: probability of achieving continence and potency 1 year after surgery. J Urol. 2010;183:1803–7.PubMedGoogle Scholar
  50. 50.
    Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Scandinavan Prostate Cancer Group Study No. 4, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977–84.PubMedGoogle Scholar
  51. 51.
    Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, SPCG-4 Investigators, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364:1708–17.Google Scholar
  52. 52.
    Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373:301–8.PubMedGoogle Scholar
  53. 53.
    Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol. 2002;20:3376–85.PubMedGoogle Scholar
  54. 54.
    Speight JL, Roach 3rd M. Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions. J Clin Oncol. 2005;23:8176–85.PubMedGoogle Scholar
  55. 55.
    Fiorica F, Berretta M, Colosimo C, et al. Safety and efficacy of radiotherapy treatment in elderly patients with localized prostate cancer: a retrospective analysis. Arch Gerontol Geriatr. 2010;51:277–82.PubMedGoogle Scholar
  56. 56.
    Pignon T, Horiot JC, Bolla M, et al. Age is not a limiting factor for radical radiotherapy in pelvic malignancies. Radiother Oncol. 1997;42:107–20.PubMedGoogle Scholar
  57. 57.
    Nguyen TD, Azria D, Brochon D, et al. Curative external beam radiotherapy in patients over 80 years of age with localized prostate cancer: a retrospective rare cancer network study. Crit Rev Oncol Hematol. 2011;74:66–71.Google Scholar
  58. 58.
    Villa S, Bedini N, Fallai C, Olmi P. External beam radiotherapy in elderly patients with clinically localized prostate adenocarcinoma: age is not a problem. Crit Rev Oncol Hematol. 2003;48:215–25.PubMedGoogle Scholar
  59. 59.
    Ogawa K, Nakamura K, Onishi H, et al. Influence of age on the pattern and outcome of external beam radiotherapy for clinically localized prostate cancer. Anticancer Res. 2006;26:1319–25.PubMedGoogle Scholar
  60. 60.
    Taira AV, Merrick GS, Butler WM, et al. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2010;79:1336–42.PubMedGoogle Scholar
  61. 61.
    Crook JM, Gomez-Iturriaga A, Wallace K, et al. Comparison of health-related quality of life 5 years after SPIRIT: surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol. 2011;29:362–8.PubMedGoogle Scholar
  62. 62.
    Roeloffzen EM, Vulpen MV, Battermann JJ, van Roermund JG, Saibishkumar EP, Monninkhof EM. Pretreatment nomogram to predict the risk of acute urinary retention after I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2011;81:737–44.PubMedGoogle Scholar
  63. 63.
    Keyes M, Miller S, Moravan V, et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys. 2009;73:1023–32.PubMedGoogle Scholar
  64. 64.
    Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2011;28:1117–23.Google Scholar
  65. 65.
    Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368–74.PubMedGoogle Scholar
  66. 66.
    Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol. 2011;29:2185–90.PubMedGoogle Scholar
  67. 67.
    Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28:126–31.PubMedGoogle Scholar
  68. 68.
    Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst. 2006;98:355–7.PubMedGoogle Scholar
  69. 69.
    O’Brien D, Loeb S, Carvalhal GF, et al. Delay of surgery in men with low risk prostate cancer. J Urol. 2010;185:2143–7.Google Scholar
  70. 70.
    Lynch CF, Cohen MB. Urinary system. Cancer. 1995;75:316–29.PubMedGoogle Scholar
  71. 71.
    Schultzel M, Saltzstein SL, Downs TM, Shimasaki S, Sanders C, Sadler GR. Late age (85 years or older) peak incidence of bladder cancer. J Urol. 2008;179:1302–5; discussion 5–6.Google Scholar
  72. 72.
    Konety BR, Joslyn SA. Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. J Urol. 2003;170:1765–71.PubMedGoogle Scholar
  73. 73.
    Taylor 3rd JA, Kuchel GA. Bladder cancer in the elderly: clinical outcomes, basic mechanisms, and future research direction. Nat Clin Pract Urol. 2009;6:135–44.PubMedGoogle Scholar
  74. 74.
    Prout Jr GR, Wesley MN, Yancik R, Ries LA, Havlik RJ, Edwards BK. Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study. Cancer. 2005;104:1638–47.PubMedGoogle Scholar
  75. 75.
    Jones JS, Campbell SC. Non-muscle-invasive bladder cancer. In: Wein AJ, editor. Campbell-Walsh urology. 9th ed. Philadelphia: Saunders Elsevier; 2007. p. 2448–67.Google Scholar
  76. 76.
    Bohle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol. 2003;170:964–9.PubMedGoogle Scholar
  77. 77.
    Cookson MS, Sarosdy MF. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol. 1992;148:797–801.PubMedGoogle Scholar
  78. 78.
    Jimenez-Cruz JF, Vera-Donoso CD, Leiva O, et al. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guerin and interferon-alpha. Urology. 1997;50:529–35.PubMedGoogle Scholar
  79. 79.
    Hurle R, Losa A, Ranieri A, Graziotti P, Lembo A. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy. J Urol. 1996;156:1602–5.PubMedGoogle Scholar
  80. 80.
    Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964–70.PubMedGoogle Scholar
  81. 81.
    Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163:1124–9.PubMedGoogle Scholar
  82. 82.
    Marans HY, Bekirov HM. Granulomatous hepatitis following intravesical bacillus Calmette-Guerin therapy for bladder carcinoma. J Urol. 1987;137:111–2.PubMedGoogle Scholar
  83. 83.
    Joudi FN, Smith BJ, O’Donnell MA, Konety BR. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol. 2006;175:1634–9; discussion 9–40.Google Scholar
  84. 84.
    Herr HW. Age and outcome of superficial bladder cancer treated with bacille Calmette-Guerin therapy. Urology. 2007;70:65–8.PubMedGoogle Scholar
  85. 85.
    Solana R, Pawelec G, Tarazona R. Aging and innate immunity. Immunity. 2006;24:491–4.PubMedGoogle Scholar
  86. 86.
    Heiner JG, Terris MK. Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guerin therapy. Urol Oncol. 2008;26:137–40.PubMedGoogle Scholar
  87. 87.
    Rawls WH, Lamm DL, Lowe BA, et al. Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer. J Urol. 1990;144:1328–30.PubMedGoogle Scholar
  88. 88.
    Gonzalez JA, Marcol BR, Wolf MC. Complications of intravesical bacillus Calmette-Guerin: a case report. J Urol. 1992;148:1892–3.PubMedGoogle Scholar
  89. 89.
    Huang GJ, Stein JP. Open radical cystectomy with lymphadenectomy remains the treatment of choice for invasive bladder cancer. Curr Opin Urol. 2007;17:369–75.PubMedGoogle Scholar
  90. 90.
    Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–66.PubMedGoogle Scholar
  91. 91.
    von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602–8.PubMedGoogle Scholar
  92. 92.
    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48:202–5; discussion 5–6.Google Scholar
  93. 93.
    Schrag D, Mitra N, Xu F, et al. Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology. 2005;65:1118–25.PubMedGoogle Scholar
  94. 94.
    Hollenbeck BK, Miller DC, Taub D, et al. Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old or older. Urology. 2004;64:292–7.PubMedGoogle Scholar
  95. 95.
    Porter MP, Kerrigan MC, Donato BM, Ramsey SD. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol. 2011;29:252–8.PubMedGoogle Scholar
  96. 96.
    Carreca I, Balducci L. Cancer chemotherapy in the older cancer patient. Urol Oncol. 2009;27:633–42.PubMedGoogle Scholar
  97. 97.
    Raj GV, Karavadia S, Schlomer B, et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer. 2010;117:276–82.PubMedGoogle Scholar
  98. 98.
    Chamie K, Hu B, Devere White RW, Ellison LM. Cystectomy in the elderly: does the survival benefit in younger patients translate to the octogenarians? BJU Int. 2008;102:284–90.PubMedGoogle Scholar
  99. 99.
    Fairey A, Chetner M, Metcalfe J, et al. Associations among age, comorbidity and clinical outcomes after radical cystectomy: results from the Alberta Urology Institute radical cystectomy database. J Urol. 2008;180:128–34; discussion 34.Google Scholar
  100. 100.
    Liberman D, Lughezzani G, Sun M, et al. Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder. Urology. 2011;77:660–6.PubMedGoogle Scholar
  101. 101.
    Konety BR, Dhawan V, Allareddy V, Joslyn SA. Impact of hospital and surgeon volume on in-hospital mortality from radical cystectomy: data from the health care utilization project. J Urol. 2005;173:1695–700.PubMedGoogle Scholar
  102. 102.
    Hollenbeck BK, Miller DC, Taub D, et al. Identifying risk factors for potentially avoidable complications following radical cystectomy. J Urol. 2005;174:1231–7; discussion 7.Google Scholar
  103. 103.
    Koppie TM, Serio AM, Vickers AJ, et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer. 2008;112:2384–92.PubMedGoogle Scholar
  104. 104.
    Donat SM, Siegrist T, Cronin A, Savage C, Milowsky MI, Herr HW. Radical cystectomy in octogenarians–does morbidity outweigh the potential survival benefits? J Urol. 2011;183:2171–7.Google Scholar
  105. 105.
    Tran E, Souhami L, Tanguay S, Rajan R. Bladder conservation treatment in the elderly population: results and prognostic factors of muscle-invasive bladder cancer. Am J Clin Oncol. 2009;32:333–7.PubMedGoogle Scholar
  106. 106.
    Montie JE. Against bladder sparing: surgery. J Urol. 1999;162:452–5; discussion 5–7.Google Scholar
  107. 107.
    Gore JL, Litwin MS. Quality of care in bladder cancer: trends in urinary diversion following radical cystectomy. World J Urol. 2009;27:45–50.PubMedGoogle Scholar
  108. 108.
    Sogni F, Brausi M, Frea B, et al. Morbidity and quality of life in elderly patients receiving ileal conduit or orthotopic neobladder after radical cystectomy for invasive bladder cancer. Urology. 2008;71:919–23.PubMedGoogle Scholar
  109. 109.
    Froehner M, Brausi MA, Herr HW, Muto G, Studer UE. Complications following radical cystectomy for bladder cancer in the elderly. Eur Urol. 2009;56:443–54.PubMedGoogle Scholar
  110. 110.
    Madersbacher S, Mohrle K, Burkhard F, Studer UE. Long-term voiding pattern of patients with ileal orthotopic bladder substitutes. J Urol. 2002;167:2052–7.PubMedGoogle Scholar
  111. 111.
    Hautmann RE, Miller K, Steiner U, Wenderoth U. The ileal neobladder: 6 years of experience with more than 200 patients. J Urol. 1993;150:40–5.PubMedGoogle Scholar
  112. 112.
    Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7:245–57.PubMedGoogle Scholar
  113. 113.
    Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer. 2008;113:78–83.PubMedGoogle Scholar
  114. 114.
    Tada S, Yamagishi J, Kobayashi H, Hata Y, Kobari T. The incidence of simple renal cyst by computed tomography. Clin Radiol. 1983;34:437–9.PubMedGoogle Scholar
  115. 115.
    Hara AK, Johnson CD, MacCarty RL, Welch TJ. Incidental extracolonic findings at CT colonography. Radiology. 2000;215:353–7.PubMedGoogle Scholar
  116. 116.
    Kouba E, Smith A, McRackan D, Wallen EM, Pruthi RS. Watchful waiting for solid renal masses: insight into the natural history and results of delayed intervention. J Urol. 2007;177:466–70; discussion 70.Google Scholar
  117. 117.
    Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998;51:203–5.PubMedGoogle Scholar
  118. 118.
    Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma-age and stage characterization and clinical implications: study of 1092 patients (1982–1997). Urology. 2000;56:58–62.PubMedGoogle Scholar
  119. 119.
    Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97:1407–27.PubMedGoogle Scholar
  120. 120.
    Verhoest G, Veillard D, Guille F, et al. Relationship between age at diagnosis and clinicopathologic features of renal cell carcinoma. Eur Urol. 2007;51:1298–304; discussion 304–5.Google Scholar
  121. 121.
    Kutikov A, Fossett LK, Ramchandani P, et al. Incidence of benign pathologic findings at partial nephrectomy for solitary renal mass presumed to be renal cell carcinoma on preoperative imaging. Urology. 2006;68:737–40.PubMedGoogle Scholar
  122. 122.
    Chen DY, Uzzo RG. Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance. J Natl Compr Canc Netw. 2009;7:635–42; quiz 43.Google Scholar
  123. 123.
    Karakiewicz PI, Suardi N, Capitanio U, et al. A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol. 2009;55:287–95.PubMedGoogle Scholar
  124. 124.
    Kutikov A, Egleston BL, Wong YN, Uzzo RG. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol. 2011;28:311–7.Google Scholar
  125. 125.
    Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol. 1969;101:297–301.PubMedGoogle Scholar
  126. 126.
    Carnevale V, Pastore L, Camaioni M, et al. Estimate of renal function in oldest old inpatients by MDRD study equation, Mayo Clinic equation and creatinine clearance. J Nephrol. 2010;23:306–13.PubMedGoogle Scholar
  127. 127.
    Canter D, Kutikov A, Sirohi M, et al. Prevalence of baseline chronic kidney disease in patients presenting with solid renal tumors. Urology. 2010;77:781–5.Google Scholar
  128. 128.
    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.PubMedGoogle Scholar
  129. 129.
    Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study. Mayo Clin Proc. 2005;80:1270–7.PubMedGoogle Scholar
  130. 130.
    Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol. 2006;7:735–40.PubMedGoogle Scholar
  131. 131.
    Thompson RH, Boorjian SA, Lohse CM, et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol. 2008;179:468–71; discussion 72–3.Google Scholar
  132. 132.
    Russo P. Partial nephrectomy for renal cancer: part I. BJU Int. 2011;105:1206–20.Google Scholar
  133. 133.
    Campbell SC, Novick AC, Belldegrun A, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182:1271–9.PubMedGoogle Scholar
  134. 134.
    Varkarakis I, Neururer R, Harabayashi T, Bartsch G, Peschel R. Laparoscopic radical nephrectomy in the elderly. BJU Int. 2004;94:517–20.PubMedGoogle Scholar
  135. 135.
    Pareek G, Yates J, Hedican S, Moon T, Nakada S. Laparoscopic renal surgery in the octogenarian. BJU Int. 2008;101:867–70.PubMedGoogle Scholar
  136. 136.
    Uzzo RG, Novick AC. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol. 2001;166:6–18.PubMedGoogle Scholar
  137. 137.
    Choueiri TK, Schutz FA, Hevelone ND, et al. Thermal ablation vs surgery for localized kidney cancer: a surveillance, epidemiology, and end results (SEER) database analysis. Urology. 2011;78:93–8.PubMedGoogle Scholar
  138. 138.
    Kunkle DA, Egleston BL, Uzzo RG. Excise, ablate or observe: the small renal mass dilemma—a meta-analysis and review. J Urol. 2008;179:1227–33; discussion 33–4.Google Scholar
  139. 139.
    Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98:1331–4.PubMedGoogle Scholar
  140. 140.
    Kunkle DA, Crispen PL, Chen DY, Greenberg RE, Uzzo RG. Enhancing renal masses with zero net growth during active surveillance. J Urol. 2007;177:849–53; discussion 53–4.Google Scholar
  141. 141.
    Crispen PL, Viterbo R, Fox EB, Greenberg RE, Chen DY, Uzzo RG. Delayed intervention of sporadic renal masses undergoing active surveillance. Cancer. 2008;112:1051–7.PubMedGoogle Scholar
  142. 142.
    Kader AK, Tamboli P, Luongo T, et al. Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience. J Urol. 2007;177:855–60; discussion 60–1.Google Scholar
  143. 143.
    Bellmunt J, Negrier S, Escudier B, Awada A, Aapro M. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev Oncol Hematol. 2009;69:64–72.PubMedGoogle Scholar
  144. 144.
    Eisen T, Oudard S, Szczylik C, et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst. 2008;100:1454–63.PubMedGoogle Scholar
  145. 145.
    Bukowski RM, Stadler WM, McDermott DF, et al. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology. 2010;78:340–7.PubMedGoogle Scholar
  146. 146.
    Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Urologic SurgeryVanderbilt University Medical CenterNashvilleUSA
  2. 2.Department of Surgery, Division of Urology, Perelman Center for Advanced MedicineHospital of the University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations